A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098
Nicholas F. Brown(University College Hospital), Paul Mulholland(University College London Hospitals NHS Foundation Trust), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute), David A. Cox(Eli Lilly (United States)), Azeem Saleem, Matthew Williams(Charing Cross Hospital), Sarah P. Blagden(Churchill Hospital), Laurie Lenox(GlaxoSmithKline (United States)), Christophe Plisson, Jianping Zhang(PAREXEL International (United States)), Yan Li(Academy of Military Medical Sciences), Jerry M. Tolson(Research Triangle Park Foundation), Kurt R. Auger(Research Triangle Park Foundation), Ronald A. Fleming(Research Triangle Park Foundation), Graham Searle, Rajendra Singh(GlaxoSmithKline (United States)), Yvonne Lewis(GlaxoSmithKline (United States))
Cited by 83
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
|Nature Medicine|2018|1.2k
Relationship Between Osteoporosis and Cardiovascular Disease in Postmenopausal Women
|Journal of Bone and Mineral Research|2005|538
Performance status score: do patients and their oncologists agree?
|British Journal of Cancer|2003|222